Hemostemix Inc.
HEM.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.27% | -17.21% | -42.31% | -30.37% | -45.07% |
| Depreciation & Amortization | -100.00% | -100.00% | -100.00% | -100.00% | -80.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.98% | -50.53% | -58.36% | -31.75% | -27.11% |
| Operating Income | 42.98% | 50.53% | 58.36% | 31.75% | 27.11% |
| Income Before Tax | 26.05% | 40.83% | 62.21% | 49.72% | 65.84% |
| Income Tax Expenses | -- | -- | -- | -- | 276.70% |
| Earnings from Continuing Operations | 37.39% | 48.49% | 65.88% | 54.18% | 58.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.39% | 48.49% | 65.88% | 54.18% | 58.19% |
| EBIT | 42.98% | 50.53% | 58.36% | 31.75% | 27.11% |
| EBITDA | 42.97% | 50.52% | 58.36% | 31.75% | 27.11% |
| EPS Basic | 42.91% | 53.94% | 70.71% | 60.07% | 68.03% |
| Normalized Basic EPS | 10.00% | 30.86% | 53.57% | 33.04% | 35.48% |
| EPS Diluted | 42.91% | 53.94% | 70.71% | 60.07% | 68.03% |
| Normalized Diluted EPS | 10.00% | 30.86% | 53.57% | 33.04% | 35.48% |
| Average Basic Shares Outstanding | 8.25% | 11.09% | 13.00% | 14.24% | 25.04% |
| Average Diluted Shares Outstanding | 8.25% | 11.09% | 13.00% | 14.24% | 25.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |